# Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis

> **NCT06031389** · NA · UNKNOWN · sponsor: **Qianfoshan Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Nephropathies

## Interventions

- **DRUG:** Henagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06031389
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031389, "Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06031389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*